Literature DB >> 1464362

Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption.

T Taube1, M N Beneton, E V McCloskey, S Rogers, M Greaves, J A Kanis.   

Abstract

We studied bone biopsies from 26 patients with myelomatosis with apparently normal skeletal metabolism. Quantitative histomorphometric measurements suggested that skeletal disease was progressive despite normocalcaemia and normal urinary excretion rates of calcium and hydroxyproline. When biopsies were divided according to the involvement of marrow by plasma cells, bone resorption--as judged by the eroded surface--increased significantly the greater plasma cell burden. Osteoclasts were frequent with moderate tumour burdens, but there was no further increase in the number of osteoclasts when plasma cell infiltration increased by more than 50% of bone marrow. Contrary to expectation, the numbers of osteoblasts and bone formation rates were increased with bone biopsies with moderate tumour burden, but were markedly lower when plasma cell infiltration occupied more than 50% of bone marrow, due to a decreased functional capacity of osteoblasts. We conclude that skeletal bone disease in myeloma is commonly progressive despite apparently stable bone disease as judged by biochemical measurements. The major mechanism of bone loss in myelomatosis is increased osteoclastic resorption but decreased bone formation contributes to bone loss with heavy plasma cell burdens. Urinary excretion of calcium and hydroxyproline provide insensitive indices of bone resorption in myelomatosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1464362     DOI: 10.1111/j.1600-0609.1992.tb00046.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  39 in total

Review 1.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 2.  Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.

Authors:  Michaela R Reagan; Lucy Liaw; Clifford J Rosen; Irene M Ghobrial
Journal:  Bone       Date:  2015-02-26       Impact factor: 4.398

3.  Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.

Authors:  Shmuel Yaccoby; Wen Ling; Fenghuang Zhan; Ronald Walker; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

Review 4.  Myeloma and Bone Disease.

Authors:  Cristina Panaroni; Andrew J Yee; Noopur S Raje
Journal:  Curr Osteoporos Rep       Date:  2017-10       Impact factor: 5.096

5.  In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma.

Authors:  Enrique M Ocio; David Vilanova; Peter Atadja; Patricia Maiso; Edvan Crusoe; Diego Fernández-Lázaro; Mercedes Garayoa; Laura San-Segundo; Teresa Hernández-Iglesias; Enrique de Alava; Wenlin Shao; Yung-Mae Yao; Atanasio Pandiella; Jesús F San-Miguel
Journal:  Haematologica       Date:  2009-11-30       Impact factor: 9.941

6.  Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.

Authors:  Ya-Wei Qiang; John D Shaughnessy; Shmuel Yaccoby
Journal:  Blood       Date:  2008-03-14       Impact factor: 22.113

7.  Activation of the acquired immune response reduces coupled bone formation in response to a periodontal pathogen.

Authors:  Yugal Behl; Michelle Siqueira; Javier Ortiz; Jingchao Li; Tesfahun Desta; Dan Faibish; Dana T Graves
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

8.  A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease.

Authors:  Bruce P Ayati; Claire M Edwards; Glenn F Webb; John P Wikswo
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

9.  Bone remodelling in monoclonal gammopathies of uncertain significance, symptomatic and nonsymptomatic myeloma.

Authors:  M Laroche; M Attal; C Dromer
Journal:  Clin Rheumatol       Date:  1996-07       Impact factor: 2.980

10.  Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis.

Authors:  Thomas Lund; Niels Abildgaard; Thomas L Andersen; Jean-Marie Delaisse; Torben Plesner
Journal:  Eur J Haematol       Date:  2010-01-13       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.